What question did this study set out to answer?

Assess the efficacy and safety of Cop 1 in slowing disability progression in patients with chronic progressive multiple sclerosis.

April 1, 1991Neurology

A placebo‐controlled, double‐blind, randomized, two‐center, pilot trial of Cop 1 in chronic progressive multiple sclerosis

View Full Paper

Ask AI

Bookmark

Authors

MBMurray B. BornsteinCity College of New York AMA. MillerMount Sinai Hospital SSSusan SlagleNational Institutes of Health

Discussion

Member takes

Implication

Randomized double-blind trial finds modest reduction in disability progression with Cop 1 in chronic progressive multiple sclerosis, suggesting potential benefit.

Key Points

Assess the efficacy and safety of Cop 1 in slowing disability progression in patients with chronic progressive multiple sclerosis.
Double-blind, placebo-controlled, randomized, two-center pilot trial enrolling 106 patients with chronic progressive multiple sclerosis.
Participants received Cop 1 or placebo and were monitored across a 24-month follow-up period using the Kurtzke Expanded Disability Status Scale (EDSS).
Confirmed EDSS progression of 1.0 or 1.5 units occurred in 9 of 51 (17.6%) Cop 1-treated patients compared to 14 of 55 (25.5%) placebo controls, with no statistically significant difference in overall survival curves.
Two-year probability of progression was 20.4% for Cop 1 versus 29.5% for placebo (p = 0.088), with a significant difference observed at 24 months in one center but not the other.
Secondary endpoints of unconfirmed progression and 0.5-unit EDSS progression showed a statistically significant difference favoring Cop 1 at 2 years (p = 0.03).

Cite This Study

Bornstein et al. (1991) studied this question.

synapsesocial.com/papers/6a71de5dc2d7c3090827216c https://doi.org/10.1212/wnl.41.4.533

View Full Paper

Ask AI

Bookmark

Implication

Randomized double-blind trial finds modest reduction in disability progression with Cop 1 in chronic progressive multiple sclerosis, suggesting potential benefit.

A placebo‐controlled, double‐blind, randomized, two‐center, pilot trial of Cop 1 in chronic progressive multiple sclerosis

Discussion

Member takes

Implication

Key Points

Cite This Study

A placebo‐controlled, double‐blind, randomized, two‐center, pilot trial of Cop 1 in chronic progressive multiple sclerosis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider